Testing HER2 in breast cancer: A comparative study on BRISH, FISH, and IHC

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 3, 2011, Pages 203-211

  Brügmann, Anja ^a   Lelkaitis, Giedrius ^a   Nielsen, Søren ^a   Jensen, Kirsten Gadgaard ^a   Jensen, Vibeke ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

breast cancer; brigthfield in situ hybridization; CEN17; chromogenic in situ hybridization (CISH); fluorescence in situ hybridization (FISH); HER2 amplification; HER2 gene; immunohistochemistry (IHC); silver in situ hybridization (SISH)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; PARAFFIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BRIGHTFIELD IN SITU HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SILVER IN SITU HYBRIDIZATION; TISSUE SLICE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; CENTROMERE; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; NEOPLASM STAGING; OBSERVER VARIATION; SENSITIVITY AND SPECIFICITY;

EID: 79955060116     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181f7118e     Document Type: Article

References (29)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
3. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20: 719-726. (Pubitemid 34111379)
4. Egervari K, Szollosi Z, Nemes Z, et al. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol. 2006;125: 155-156. (Pubitemid 43089739)
5. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320-368.
6. Cuadros M, Villegas R. Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol. 2009;17:1-7.
7. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005;6:240-246. (Pubitemid 47050800)
8. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291: 1972-1977. (Pubitemid 38544278)
9. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323-1333.
10. Penault-Llorca F, Bilous M, Dowsett M, et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol. 2009;132:539-548.
11. Sapino A, Coccorullo Z, Cassoni P, et al. Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains. Histopathology. 2003;43:354-362. (Pubitemid 37249149)
12. Laakso M, Tanner M, Isola J. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol. 2006;210:3-9. (Pubitemid 44288174)
13. Tanner M, Gancberg D, Di LA, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000;157:1467-1472.
14. Gruver AM, Peerwani Z, Tubbs RR. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol. 2010;63:210-219.
15. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, et al. Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH). Diagn Pathol. 2008;3:41.
16. Francis GD, Jones MA, Beadle GF, et al. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol. 2009;18:88-95.
17. Carbone A, Botti G, Gloghini A, et al. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn. 2008;10:527-536.
18. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847. (Pubitemid 28331029)
19. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943-1949. (Pubitemid 32012762)
20. Egervari K, Szollosi Z, Nemes Z. Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract. 2007;203: 169-177.
21. Horvath L, Henshall S. The application of tissue microarrays to cancer research. Pathology. 2001;33:125-129. (Pubitemid 32453402)
22. Kumar B, De SM, Venter DJ, et al. Tissue microarrays: a practical guide. Pathology. 2004;36:295-300. (Pubitemid 39178967)
23. Selvarajan S, Tan SY, Sii LH, et al. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays? Pathology. 2006;38:316-320. (Pubitemid 44266629)
24. Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007;451:19-25.
25. Shousha S, Peston D, mo-Takyi B, et al. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology. 2009;54:248-253.
26. Papouchado BG, Myles J, Lloyd RV, et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol. 2010;34:767-776.
27. Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization? Am J Clin Pathol. 2005;123:237-243. (Pubitemid 40194085)
28. Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol. 2009;18:96-102.
29. Garcia-Caballero T, Grabau D, Green AR, et al. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology. 2010;56:472-480.